{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T15:23:19Z","timestamp":1769268199690,"version":"3.49.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T00:00:00Z","timestamp":1502755200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s11940-017-0465-2","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T20:17:59Z","timestamp":1502741879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Critical Evaluation on MOH Current Treatments"],"prefix":"10.1007","volume":"19","author":[{"given":"Andrea","family":"Negro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Curto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luana","family":"Lionetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Guerzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi Alberto","family":"Pini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,15]]},"reference":[{"key":"465_CR1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629\u2013808.","journal-title":"Cephalalgia"},{"key":"465_CR2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10194-011-0342-4","volume":"12","author":"TJ Steiner","year":"2011","unstructured":"Steiner TJ, Birbeck GL, Jensen R, Katsarava Z, Martelletti P, Stovner LJ. The Global Campaign, World Health Organization and Lifting The Burden: collaboration in action. J Headache Pain. 2011;12:273\u20134.","journal-title":"J Headache Pain"},{"key":"465_CR3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","volume":"13","author":"LM Bloudek","year":"2012","unstructured":"Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13:361\u201378.","journal-title":"J Headache Pain"},{"key":"465_CR4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","volume":"386","author":"Global Burden of Disease Study 2013 Collaborators","year":"2015","unstructured":"Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743\u2013800.","journal-title":"Lancet"},{"key":"465_CR5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s10194-015-0544-2","volume":"16","author":"TJ Steiner","year":"2015","unstructured":"Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P. Headache disorders are third cause of disability worldwide. J Headache Pain. 2015;16:58.","journal-title":"J Headache Pain"},{"key":"465_CR6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s10194-016-0699-5","volume":"17","author":"TJ Steiner","year":"2016","unstructured":"\u2022 Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain. 2016;17:104. This article reports how migraine is ranked by WHO as the third of disability in under 50s.","journal-title":"J Headache Pain"},{"key":"465_CR7","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.0b013e3181974b19","volume":"72","author":"RB Lipton","year":"2009","unstructured":"Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology. 2009;72:S3\u20137.","journal-title":"Neurology"},{"key":"465_CR8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","volume":"81","author":"DC Buse","year":"2010","unstructured":"Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428\u201332.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"465_CR9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301\u201315.","journal-title":"Cephalalgia"},{"key":"465_CR10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/JOM.0b013e3181c1dc56","volume":"52","author":"WF Stewart","year":"2010","unstructured":"Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB. Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med. 2010;52:8\u201314.","journal-title":"J Occup Environ Med"},{"key":"465_CR11","doi-asserted-by":"crossref","unstructured":"Negro A, D\u2019Alonzo L, Martelletti P. Chronic migraine: comorbidities, risk factors, and rehabilitation. Intern Emerg Med. 2010;(Suppl 1):S13\u20139.","DOI":"10.1007\/s11739-010-0457-7"},{"key":"465_CR12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s10194-016-0649-2","volume":"17","author":"C Lampl","year":"2016","unstructured":"Lampl C, Thomas H, Tassorelli C, Katsarava Z, La\u00ednez JM, Lant\u00e9ri-Minet M, et al. Headache, depression and anxiety: associations in the Eurolight project. J Headache Pain. 2016;17:59.","journal-title":"J Headache Pain"},{"key":"465_CR13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1056\/NEJMct0910887","volume":"363","author":"E Loder","year":"2010","unstructured":"Loder E. Triptan therapy in migraine. N Engl J Med. 2010;363:63\u201370.","journal-title":"N Engl J Med"},{"key":"465_CR14","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1111\/j.1526-4610.2004.04105.x","volume":"44","author":"DW Dodick","year":"2004","unstructured":"Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache. 2004;44:S20\u201330.","journal-title":"Headache"},{"key":"465_CR15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1212\/01.wnl.0000323925.29520.e7","volume":"71","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559\u201366.","journal-title":"Neurology"},{"key":"465_CR16","first-page":"1401","volume":"15","author":"A Negro","year":"2011","unstructured":"Negro A, Rocchietti-March M, Fiorillo M, Martelletti P. Chronic migraine: current concepts and ongoing treatments. Eur Rev Med Pharmacol Sci. 2011;15:1401\u201320.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"465_CR17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1517\/17425255.2016.1154042","volume":"12","author":"L Lionetto","year":"2016","unstructured":"Lionetto L, Borro M, Curto M, Capi M, Negro A, Cipolla F, et al. Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. Expert Opin Drug Metab Toxicol. 2016;12:399\u2013406.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"465_CR18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, PREEMPT 1 Chronic Migraine Study Group, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793\u2013803.","journal-title":"Cephalalgia"},{"key":"465_CR19","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, PREEMPT 2 Chronic Migraine Study Group, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804\u201314.","journal-title":"Cephalalgia"},{"key":"465_CR20","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, PREEMPT Chronic Migraine Study Group, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921\u201336.","journal-title":"Headache"},{"issue":"15","key":"465_CR21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1129-2377-15-47","volume":"28","author":"P Martelletti","year":"2014","unstructured":"\u2022 Martelletti P, Katsarava Z, Lampl C, Magis D, Bendtsen L, Negro A, et al. Refractory chronic migraine: a consensus statement on clinical definition from the European headache federation. J Headache Pain. 2014;28(15):47. An important attempt to clinically define refractory chronic migraine.","journal-title":"J Headache Pain"},{"key":"465_CR22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(04)00824-5","volume":"3","author":"HC Diener","year":"2004","unstructured":"Diener HC, Limmroth V. Medication overuse headache: a worldwide problem. Lancet Neurol. 2004;3:475\u201383.","journal-title":"Lancet Neurol"},{"key":"465_CR23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","volume":"30","author":"JL Natoli","year":"2010","unstructured":"Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30:599\u2013609.","journal-title":"Cephalalgia"},{"key":"465_CR24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s10194-016-0696-8","volume":"17","author":"K Thorlund","year":"2016","unstructured":"\u2022\u2022 Thorlund K, Sun-Edelstein C, Druyts E, Kanters S, Ebrahim S, Bhambri R, et al. Risk of medication overuse headache across classes of treatments for acute migraine. J Headache Pain. 2016;17:107. This study evaluated whether certain classes of acute migraine drugs are more likely to elicit MOH than others.","journal-title":"J Headache Pain"},{"key":"465_CR25","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1526-4610.2006.00442.x","volume":"46","author":"CA Meskunas","year":"2006","unstructured":"Meskunas CA, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache. 2006;46:766\u201372.","journal-title":"Headache"},{"key":"465_CR26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10194-011-0388-3","volume":"12","author":"A Negro","year":"2011","unstructured":"Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12:593\u2013601.","journal-title":"J Headache Pain"},{"key":"465_CR27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1129-2377-14-43","volume":"14","author":"P Jonsson","year":"2013","unstructured":"Jonsson P, Jakobsson A, Hensing G, Linde M, Moore C, Hedenrud T. Holding on to the indispensable medication\u2014a grounded theory on medication use from the perspective of persons with medication overuse headache. J Headache Pain. 2013;14:43.","journal-title":"J Headache Pain"},{"key":"465_CR28","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/j.1468-2982.2006.01210.x","volume":"26","author":"NJ Wiendels","year":"2006","unstructured":"Wiendels NJ, Knuistingh Neven A, Rosendaal FR, Spinhoven P, Zitman FG, Assendelft WJ, et al. Chronic frequent headache in the general population: prevalence and associated factors. Cephalalgia. 2006;26:1434\u201342.","journal-title":"Cephalalgia"},{"key":"465_CR29","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.0b013e3181eee244","volume":"75","author":"L Robberstad","year":"2010","unstructured":"Robberstad L, Dyb G, Hagen K, Stovner LJ, Holmen TL, Zwart JA. An unfavourable lifestyle and recurrent headaches among adolescents: the HUNT study. Neurology. 2010;75:712\u20137.","journal-title":"Neurology"},{"key":"465_CR30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pain.2011.08.018","volume":"153","author":"K Hagen","year":"2012","unstructured":"Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart JA. Risk factors for medication overuse headache: an 11-year follow-up study. The Nord-Tr\u00f8ndelag Health Studies. Pain. 2012;153:56\u201361.","journal-title":"Pain"},{"key":"465_CR31","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0333102414563087","volume":"35","author":"SH Schramm","year":"2015","unstructured":"Schramm SH, Moebus S, Lehmann N, Galli U, Obermann M, Bock E, et al. The association between stress and headache: a longitudinal population-based study. Cephalalgia. 2015;35:853\u201363.","journal-title":"Cephalalgia"},{"key":"465_CR32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/0333102415578430","volume":"36","author":"M Westergaard","year":"2016","unstructured":"Westergaard M, Gl\u00fcmer C, Hansen E, Jensen R. Medication overuse, healthy lifestyle behaviours and stress in chronic headache: results from a representative population-based survey. Cephalalgia. 2016;36:15\u201328.","journal-title":"Cephalalgia"},{"key":"465_CR33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1526-4610.2008.01257.x","volume":"48","author":"S Cevoli","year":"2009","unstructured":"Cevoli S, Sancisi E, Grimaldi D, Pierangeli G, Zanigni S, Nicodemo M, et al. Family history for chronic headache and drug overuse as a risk factor for headache chronification. Headache. 2009;48:412\u20138.","journal-title":"Headache"},{"key":"465_CR34","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1468-2982.2008.01555.x","volume":"28","author":"S Silberstein","year":"2008","unstructured":"Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008;28:484\u201395.","journal-title":"Cephalalgia"},{"key":"465_CR35","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1468-2982.2006.01190.x","volume":"26","author":"P Zeeberg","year":"2006","unstructured":"Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia. 2006;26:1192\u20138.","journal-title":"Cephalalgia"},{"key":"465_CR36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/0333102415593088","volume":"36","author":"C Chiang","year":"2016","unstructured":"Chiang C, Schwedt T, Wang S, Dodick D. Treatment of medication-overuse headache: a systematic review. Cephalalgia. 2016;36:371\u201386.","journal-title":"Cephalalgia"},{"key":"465_CR37","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1046\/j.1468-2982.2003.00648.x","volume":"23","author":"AV Krymchantowski","year":"2003","unstructured":"Krymchantowski AV, Moreira PF. Outpatient detoxification in chronic migraine: comparison of strategies. Cephalalgia. 2003;23:982\u201393.","journal-title":"Cephalalgia"},{"key":"465_CR38","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1468-2982.2006.01175.x","volume":"26","author":"P Rossi","year":"2006","unstructured":"Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G. Advice alone vs structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006;26:1097\u2013110.","journal-title":"Cephalalgia"},{"key":"465_CR39","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Tassorelli C, Jensen R, Allena M, De Icco R, Sances G, Katsarava Z, et al, Nappi G; the COMOESTAS Consortium. A consensus protocol for the management of medication-overuse headache: evaluation in a multicentric, multinational study. Cephalalgia 2014;34:645\u2013655. This study we defined and tested a consensus protocol for the management of MOH on a large population of patients distributed in different countries.","DOI":"10.1177\/0333102414521508"},{"key":"465_CR40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/jnnp-2014-308548","volume":"86","author":"ES Kristoffersen","year":"2015","unstructured":"Kristoffersen ES, Straand J, Vetvik KG, Benth J\u0160, Russell MB, Lundqvist C. Brief intervention for medication-overuse headache in primary care. The BIMOH study: a double-blind pragmatic cluster randomised parallel controlled trial. J Neurol Neurosurg Psychiatry. 2015;86:505\u201312.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"465_CR41","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1007\/s10072-009-0081-3","volume":"30","author":"F Andrasik","year":"2009","unstructured":"Andrasik F, Grazzi L, Usai S, Buse DC, Bussone G. Non-pharmacological approaches to treating chronic migraine with medication overuse. Neurol Sci. 2009;30:S89\u201393.","journal-title":"Neurol Sci"},{"key":"465_CR42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s10194-016-0679-9","volume":"17","author":"M Rausa","year":"2016","unstructured":"Rausa M, Palomba D, Cevoli S, Lazzerini L, Sancisi E, Cortelli P, et al. Biofeedback in the prophylactic treatment of medication overuse headache: a pilot randomized controlled trial. J Headache Pain. 2016;17:87.","journal-title":"J Headache Pain"},{"key":"465_CR43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1468-2982.2000.00028.x","volume":"20","author":"AV Krymchantowski","year":"2000","unstructured":"Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia. 2000;20:107\u201313.","journal-title":"Cephalalgia"},{"key":"465_CR44","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1468-2982.2007.01488.x","volume":"28","author":"L Pageler","year":"2008","unstructured":"Pageler L, Katsarava Z, Diener HC, Limmroth V. Prednisone versus placebo in withdrawal therapy following medication overuse headache. Cephalalgia. 2008;28:152\u20136.","journal-title":"Cephalalgia"},{"key":"465_CR45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/head.12970","volume":"57","author":"AV Krymchantowski","year":"2017","unstructured":"Krymchantowski AV, Tepper SJ, Jevoux C, Valen\u00e7a M. Medication-overuse headache: protocols and outcomes in 149 consecutive patients in a tertiary Brazilian headache center. Headache. 2017;57:87\u201396.","journal-title":"Headache"},{"key":"465_CR46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/01.wnl.0000263652.46222.e8","volume":"69","author":"MG B\u00f8e","year":"2007","unstructured":"B\u00f8e MG, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache. Neurology. 2007;69:26\u201331.","journal-title":"Neurology"},{"key":"465_CR47","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10072-008-0913-6","volume":"29","author":"L Grazzi","year":"2008","unstructured":"Grazzi L, Andrasik F, Usai S, Bussone G. In-patient vs. day-hospital withdrawal treatment for chronic migraine with medication overuse and disability assessment: results at one-year follow-up. Neurol Sci. 2008;29:161\u20133.","journal-title":"Neurol Sci"},{"key":"465_CR48","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1468-2982.2006.01198.x","volume":"26","author":"J Saper","year":"2006","unstructured":"Saper J, Lake A III. Medication overuse headache: type I and type II. Cephalalgia. 2006;26:1262.","journal-title":"Cephalalgia"},{"key":"465_CR49","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1007\/s10072-010-0319-0","volume":"31","author":"F Valguarnera","year":"2010","unstructured":"Valguarnera F, Tanganelli P. The efficacy of withdrawal therapy in subjects with chronic daily headache and medication overuse following prophylaxis with topiramate and amitriptyline. Neurol Sci. 2010;31:S175\u20137.","journal-title":"Neurol Sci"},{"key":"465_CR50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1526-4610.2010.01631.x","volume":"50","author":"M Trucco","year":"2010","unstructured":"Trucco M, Meineri P, Ruiz L, Gionco M, Gruppo Neurologico Ospedaliero Interregionale per lo Studio delle Cefalee (Neurological Hospital Interregional Group for the Study of Headaches). Medication overuse headache: withdrawal and prophylactic therapeutic regimen. Headache. 2010;50:989\u201397.","journal-title":"Headache"},{"key":"465_CR51","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/j.1468-2982.2008.01659.x","volume":"28","author":"P Rossi","year":"2008","unstructured":"Rossi P, Faroni JV, Nappi G. Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia. 2008;28:1196\u2013200.","journal-title":"Cephalalgia"},{"key":"465_CR52","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1046\/j.1468-2982.1996.1607481.x","volume":"16","author":"P Schnider","year":"1996","unstructured":"Schnider P, Aull S, Baumgartner C, Marterer A, W\u00f6ber C, Zeiler K, et al. Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five-year follow-up. Cephalalgia. 1996;16:481\u20135.","journal-title":"Cephalalgia"},{"key":"465_CR53","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s004150050458","volume":"248","author":"S Evers","year":"1999","unstructured":"Evers S, Suhr B, Bauer B, Grotemeyer KH, Husstedt IW. A retrospective long-term analysis of the epidemiology and features of drug-induced headache. J Neurol. 1999;248:802\u20139.","journal-title":"J Neurol"},{"key":"465_CR54","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000052134","volume":"45","author":"G Fritsche","year":"2001","unstructured":"Fritsche G, Eberl A, Katsarava Z, Limmroth V, Diener HC. Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol. 2001;45:229\u201335.","journal-title":"Eur Neurol"},{"key":"465_CR55","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1046\/j.1468-2982.2001.00288.x","volume":"21","author":"LA Pini","year":"2001","unstructured":"Pini LA, Cicero AF, Sandrini M. Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia. 2001;21:878\u201383.","journal-title":"Cephalalgia"},{"key":"465_CR56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1468-2982.2004.00789.x","volume":"25","author":"Z Katsarava","year":"2005","unstructured":"Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener HC, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005;25:12\u20135.","journal-title":"Cephalalgia"},{"key":"465_CR57","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10194-010-0285-1","volume":"12","author":"K Hagen","year":"2011","unstructured":"Hagen K, Albretsen C, Vilming ST, Salvesen R, Gronning M, Helde G, et al. A 4-year follow-up of patients with medication-overuse headache previously included in a randomized multicenter study. J Headache Pain. 2011;12:315\u201322.","journal-title":"J Headache Pain"},{"key":"465_CR58","doi-asserted-by":"crossref","unstructured":"Zidverc-Trajkovic JJ, Pekmezovic T, Jovanovic Z, Pavlovic A, Mijajlovic M, Radojicic A, Sternic N. Long-term predictors of remission in patients treated for medication-overuse headache at a specialized headache center: a prospective cohort study. Cephalalgia 2016 9.","DOI":"10.1177\/0333102416683918"},{"key":"465_CR59","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/head.12979","volume":"57","author":"A Raggi","year":"2017","unstructured":"Raggi A, Giovannetti AM, Leonardi M, Sansone E, Schiavolin S, Curone M, et al. Predictors of 12-months relapse after withdrawal treatment in hospitalized patients with chronic migraine associated with medication overuse: a longitudinal observational study. Headache. 2017;57:60\u201370.","journal-title":"Headache"},{"key":"465_CR60","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1468-1331.2009.02571.x","volume":"16","author":"MG Boe","year":"2009","unstructured":"Boe MG, Salvesen R, Mygland A. Chronic daily headache with medication overuse: predictors of outcome 1 year after withdrawal therapy. Eur J Neurol. 2009;16:705\u201312.","journal-title":"Eur J Neurol"},{"key":"465_CR61","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/14737175.2016.1200973","volume":"16","author":"A Negro","year":"2016","unstructured":"Negro A, Curto M, Luana L, Giamberardino MA, Martelletti P. Chronic migraine treatment: from onabotulinumtoxinA onwards. Expert Rev Neurother. 2016;16:1217\u201327.","journal-title":"Expert Rev Neurother"},{"key":"465_CR62","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s10194-016-0634-9","volume":"17","author":"S Guerzoni","year":"2016","unstructured":"Guerzoni S, Pellesi L, Baraldi C, Pini LA. Increased efficacy of regularly repeated cycles with onabotulinumtoxinA in MOH patients beyond the first year of treatment. J Headache Pain. 2016;17:48.","journal-title":"J Headache Pain"},{"key":"465_CR63","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s10194-016-0702-1","volume":"17","author":"I Aicua-Rapun","year":"2016","unstructured":"Aicua-Rapun I, Mart\u00ednez-Velasco E, Rojo A, Hernando A, Ruiz M, Carreres A, et al. Real-life data in 115 chronic migraine patients treated with onabotulinumtoxinA during more than one year. J Headache Pain. 2016;17:112.","journal-title":"J Headache Pain"},{"key":"465_CR64","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1186\/s40064-015-1636-9","volume":"4","author":"A Negro","year":"2015","unstructured":"Negro A, Curto M, Lionetto L, Crialesi D, Martelletti P. OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. Spring. 2015;4:826.","journal-title":"Spring"},{"key":"465_CR65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-016-0591-3","volume":"17","author":"A Negro","year":"2015","unstructured":"\u2022\u2022 Negro A, Curto M, Lionetto L, Martelletti P. A two years open-label prospective study of onabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17:1. This is the largest and longest postmarketing study of doses comparison with onabotulinumtoxinA in a real-life clinical setting for CM patients with MOH.","journal-title":"J Headache Pain"},{"key":"465_CR66","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.1468-1331.2007.01869.x","volume":"14","author":"MJ L\u00e1inez","year":"2007","unstructured":"L\u00e1inez MJ, Freitag FG, Pfeil J, Ascher S, Olson WH, Schwalen S. Time course of adverse events most commonly associated with topiramate for migraine prevention. Eur J Neurol. 2007;14:900\u20136.","journal-title":"Eur J Neurol"},{"key":"465_CR67","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","volume":"27","author":"HC Diener","year":"2007","unstructured":"Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, TOPMAT-MIG-201(TOP-CHROME) Study Group, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814\u201323.","journal-title":"Cephalalgia"},{"key":"465_CR68","unstructured":"NICE; Botulinum toxin type A for the prevention of headaches in adults with chronic migraine; Technology appraisal guidance [TA260]; https:\/\/www.nice.org.uk\/guidance\/ta260 . Last accessed 13 March 2017."},{"key":"465_CR69","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1592\/phco.29.7.784","volume":"29","author":"AJ Shuhendler","year":"2009","unstructured":"Shuhendler AJ, Lee S, Siu M, Ondovcik S, Lam K, et al. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy. 2009;29:784\u201391.","journal-title":"Pharmacotherapy"},{"key":"465_CR70","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1526-4610.2007.00853.x","volume":"47","author":"SK Aurora","year":"2007","unstructured":"Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache. 2007;47:486\u201399.","journal-title":"Headache"},{"key":"465_CR71","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barr\u00e9 J, Katsarava Z, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19:703\u201311.","journal-title":"Eur J Neurol"},{"key":"465_CR72","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1526-4610.2012.02191.x","volume":"52","author":"SB Munksgaard","year":"2012","unstructured":"Munksgaard SB, Bendtsen L, Jensen RH. Treatment-resistant medication overuse headache can be cured. Headache. 2012;52:1120\u20139.","journal-title":"Headache"},{"key":"465_CR73","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s10194-016-0707-9","volume":"17","author":"S Schramm","year":"2016","unstructured":"Schramm S, Uluduz D, Gouveia RG, Jensen R, Siva A, Uygunoglu U, et al. Headache service quality: evaluation of quality indicators in 14 specialist-care centres. J Headache Pain. 2016;17:111.","journal-title":"J Headache Pain"},{"key":"465_CR74","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/head.12941","volume":"56","author":"RB Lipton","year":"2016","unstructured":"Lipton RB, Munjal S, Buse DC, Fanning KM, Bennett A, Reed ML. Predicting inadequate response to acute migraine medication: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2016;56:1635\u201348.","journal-title":"Headache"},{"key":"465_CR75","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s11739-016-1489-4","volume":"11","author":"MA Giamberardino","year":"2016","unstructured":"\u2022 Giamberardino MA, Affaitati G, Curto M, Negro A, Costantini R, Martelletti P. Anti-CGRP monoclonal antibodies in migraine: current perspectives. Intern Emerg Med. 2016;11:1045\u201357. An up-to-date current review on the newest treatments for the primary headache disorders.","journal-title":"Intern Emerg Med"},{"key":"465_CR76","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","volume":"331","author":"SD Silberstein","year":"2013","unstructured":"Silberstein SD, Blumenfield AM, Cady RK, Turner IM, Lipton RB, Deiner HC, et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331:48\u201356.","journal-title":"J Neurol Sci"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-017-0465-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-017-0465-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-017-0465-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T07:57:42Z","timestamp":1570003062000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-017-0465-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,15]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1007\/s11940-017-0465-2","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,15]]},"article-number":"32"}}